News | November 23, 2010

Balloon Catheter Surpasses Filter-Based Systems for Treating Lower Extremity Embolisms

November 23, 2010 – A device for peripheral transluminal angioplasty (PTA) and for capturing and containing embolic material during angioplasty in the lower extremities has been approved by the U.S. Food and Drug Administration (FDA). The Proteus device, by Angioslide, can be used in the femoral, iliac, iliofemoral, popliteal, tibial, peroneal and profunda arteries.

“One of the most devastating complications arising from peripheral transluminal angioplasty is embolic material that escapes to a point that is anatomically distant from the location of the embolism,” said Gunnar Tepe, M.D., head of diagnostic and interventional radiology at the Academic Hospital of Rosenheim (Rosenheim, Germany). “Such complications can lead to a spectrum of consequences up to an including the loss of limb or life.”

Filter-based systems of embolic protection have several advantages and have been the primary mechanism for capturing embolic debris. However, limitations include the ability to deliver the filter, the added cost, lack of FDA clearance for infrainguinal use and filter-caused arterial trauma.

The device is used as an angioplasty balloon, with a technical success rate of 97 percent to 99 percent, and a pooled clinically significant vessel dissection rate of less than 5 percent. Porcine models have shown that there is no increased vessel injury from the inrolling mechanism of the balloon.

It combines the ability to perform angioplasty while also capturing debris that could potentially embolize during the procedure. Initially, the device functions as a normal angioplasty balloon. After angioplasty, the balloon is deflated to 2 atm., when arterial flow remains occluded. The balloon is then infolded upon itself, essentially sucking up potential embolic debris.

For more information:

Related Content

FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA
News | Stents Carotid| November 18, 2016
November 18, 2016 — InspireMD Inc.
Sponsored Content | Videos | Heart Valve Technology| November 08, 2016
Studies have shown transcatheter aortic valve replacement (TAVR) has an increased risk of stroke and cerebral damage
TAVR, post-procedure, brain lesions, delirium, TCT 2016, Peter R. Stella
News | Heart Valve Technology| November 07, 2016
Keystone Heart Ltd. announced that data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016...
Sentinel, TAVR, TAVI, embloic protection
News | Heart Valve Technology| November 07, 2016
November 7, 2016 – A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Overlay Init